免疫功能正常与免疫抑制患者感染性休克的时间病程
该单中心回顾性研究纳入2008至2015年ICU入住48小时内诊断感染性休克的801例患者,其中305例(38%)存在免疫抑制,分为实体瘤(122例)、血液恶性肿瘤(106例)和非恶性免疫抑制(77例)。总体3天、ICU内和院内死亡率分别为14.1%、37.3%和41.3%。实体瘤患者院内死亡风险升高(病因特异性HR 2.20,95%CI 1.64-2.96,P<0.001)。3天存活者中211例(33%)发生ICU获得性感染,95例(11.8%)和70例(8.7%)分别发生严重缺血或出血并发症;免疫状态与ICU获得性感染无关联,非恶性免疫抑制与严重缺血事件独立相关(HR 2.12,95%CI 1.14-3.96,P=0.02),血液恶性肿瘤与出血独立相关(HR 3.17,95%CI 1.41-7.13,P=0.005)。
要点
- 801例感染性休克患者中305例(38%)存在免疫抑制,总体院内死亡率41.3%,ICU内死亡率37.3%,3天死亡率14.1%。
- 实体瘤患者院内死亡风险较非免疫抑制患者升高(病因特异性HR 2.20,95%CI 1.64-2.96,P<0.001)。
- 3天存活者中211例(33%)发生ICU获得性感染,免疫状态与ICU获得性感染发生无关联。
- 非恶性免疫抑制与严重缺血事件独立相关(病因特异性HR 2.12,95%CI 1.14-3.96,P=0.02)。
- 血液恶性肿瘤与出血独立相关(病因特异性HR 3.17,95%CI 1.41-7.13,P=0.005)。
适用人群与场景
- ICU入住48小时内诊断为感染性休克的患者。
- 按免疫状态分为非免疫抑制和免疫抑制,免疫抑制再分为实体瘤、血液恶性肿瘤和非恶性免疫抑制。
研究设计与关键结果
- 研究类型:8年(2008-2015)单中心回顾性研究,纳入801例ICU入住48小时内诊断感染性休克的患者。
- 免疫抑制分布:305例(38%)免疫抑制,其中实体瘤122例、血液恶性肿瘤106例、非恶性免疫抑制77例。
- 死亡率:总体3天死亡率14.1%,ICU内死亡率37.3%,院内死亡率41.3%。
- 实体瘤患者院内死亡风险升高(病因特异性HR 2.20,95%CI 1.64-2.96,P<0.001)。
- ICU获得性感染:3天存活者中211例(33%)发生,免疫状态与ICU获得性感染无关联。
- 严重并发症:95例(11.8%)发生严重缺血事件,70例(8.7%)发生严重出血事件。
- 非恶性免疫抑制与严重缺血事件独立相关(病因特异性HR 2.12,95%CI 1.14-3.96,P=0.02)。
- 血液恶性肿瘤与出血独立相关(病因特异性HR 3.17,95%CI 1.41-7.13,P=0.005)。
证据类型、等级与局限
- 证据类型:单中心回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,基础免疫状态影响感染性休克的病程及对ICU获得性并发症的易感性,强调脓毒症综合征与合并症相关的复杂性,并提出临床研究中相关终点选择的问题。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To address the impact of underlying immune conditions on the course of septic shock with respect to both mortality and the development of acute infectious and noninfectious complications.
DESIGN: An 8-year (2008-2015) monocenter retrospective study.
SETTING: A medical ICU in a tertiary care center.
PATIENTS: Patients diagnosed for septic shock within the first 48 hours of ICU admission were included. Patients were classified in four subgroups with respect to their immune status: nonimmunocompromised and immunocompromised distributed into hematologic or solid malignancies and nonmalignant immunosuppression. Outcomes were in-hospital death and the development of ischemic and hemorrhagic complications and ICU-acquired infections. The determinants of death and complications were addressed by multivariate competing risk analysis.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Eight hundred one patients were included. Among them, 305 (38%) were immunocompromised, distributed into solid tumors (122), hematologic malignancies (106), and nonmalignant immunosuppression (77). The overall 3-day, in-ICU, and in-hospital mortality rates were 14.1%, 37.3%, and 41.3%, respectively. Patients with solid tumors displayed increased in-hospital mortality (cause-specific hazard, 2.20 [95% CI, 1.64-2.96]; p < 0.001). ICU-acquired infections occurred in 211 of the 3-day survivors (33%). In addition, 95 (11.8%) and 70 (8.7%) patients exhibited severe ischemic or hemorrhagic complications during the ICU stay. There was no association between the immune status and the occurrence of ICU-acquired infections. Nonmalignant immunosuppression and hematologic malignancies were independently associated with increased risks of severe ischemic events (cause-specific hazard, 2.12 [1.14-3.96]; p = 0.02) and hemorrhage (cause-specific hazard, 3.17 [1.41-7.13]; p = 0.005), respectively.
CONCLUSIONS: The underlying immune status impacts on the course of septic shock and on the susceptibility to ICU-acquired complications. This emphasizes the complexity of sepsis syndromes in relation with comorbid conditions and raises the question of the relevant endpoints in clinical studies.
参考来源
- Jamme M, Daviaud F, Charpentier J, et al. Time Course of Septic Shock in Immunocompromised and Nonimmunocompromised Patients. Crit Care Med. 2017. PMID: 28937407. doi:10.1097/CCM.0000000000002722
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。